SESAME final results - Advancing patient care with clinical validation

Faced with stroke and looking for the kind of devices – and procedure – that could offer good rates of recanalization and low rates of embolization to new territories after the occlusion?
Then join Jonathan Downer (UK) and Markus Möhlenbruch (Germany) in this revealing discussion from LINNC Paris 2024 with results from the SESAME study looking at Microvention’s SOFIA™ and SOFIA™ PLUS catheters.

SESAME was designed as the first good clinical practice (GCP) study of first-line aspiration in patients suffering from large vessel occlusion in the anterior circulation with patients enrolled in the study treated within the first 6 hours after presentation.

SESAME’s primary clinical outcome at 90 days was good, with a functional outcome of mRS 0-2 in over 60% of the cases along with an observed 10-point drop in the NIH stroke score 24 hours after treatment – results that speak for themselves and underline the efficacy and safety of the SOFIA™ and SOFIA™ PLUS catheters used in the study.

Discover what you need to maximize the efficacy of aspiration as a first-line technique and how aspiration worked in terms of non-target embolization.
With insights on how best to prepare your strategy – such as choosing the largest caliber aspiration catheter, whether to use a syringe or pump strategy, or when you should start aspiration of the clot – this interview will prove fascinating.

Microvention is perfecting the tools you need to treat stroke – and the SESAME Study proves this with the results of SOPHIA and SOPHIA Plus in action – join us here and understand the evidence and clinical knowledge you need to use them today.

Sponsored by MicroVention